This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
== Hazards == Bottles of di-tert-butyl dicarbonate buildup of internal pressure in sealed containers caused by its slow decomposition to di-tert-butyl carbonate and ultimately tert-butanol and CO2 in the presence of moisture. For this reason, it is usually sold and stored in plastic bottles rather than glass ones. The main hazard of the reagent is its inhalational toxicity. Its median lethal concentration of 100 mg/m3 over 4 hours in rats is comparable to that of phosgene (49 mg/m3 over 50 min in rats).
=== Post-menopausal women === In post-menopausal women, breast atrophy is aggravated by the inelasticity of over-stretched, aged skin. This is due in part to the reduction in estrogen, which affects all body tissues, including breast tissue. The loss of estrogen reduces breast size and fullness. Estrogen is also essential to maintaining a fibrous protein called collagen, which makes up much of the breast's connective tissue.
Indium has 39 known isotopes, ranging in mass number from 97 to 135. Only two isotopes occur naturally as primordial nuclides: indium-113, the only stable isotope, and indium-115, which has a half-life of 4.41×1014 years, four orders of magnitude greater than the age of the Universe and nearly 30,000 times greater than half-life of thorium-232. The half-life of 115In is very long because the beta decay to 115Sn is spin-forbidden. Indium-115 makes up 95.7% of all indium. Indium is one of three known elements (the others being tellurium and rhenium) of which the stable isotope is less abundant in nature than the long-lived primordial radioisotopes. The stablest artificial isotope is indium-111, with a half-life of approximately 2.8 days. All other isotopes have half-lives shorter than 5 hours. Indium also has 47 meta states, among which indium-114m1 (half-life about 49.51 days) is the most stable, more stable than the ground state of any indium isotope other than the primordial. All decay by isomeric transition. The indium isotopes lighter than 113In predominantly decay through electron capture or positron emission to form cadmium isotopes, while the indium isotopes heavier than 113In predominantly decay through beta-minus decay to form tin isotopes.
== Side effects == Rasburicase administration can cause anaphylaxis (incidence unknown); methemoglobinemia may occur in susceptible individuals such as those with G6PDH deficiency due to the production of hydrogen peroxide in the urate oxidase reaction. Testing patients for G6PDH deficiency prior to starting a course of rasburicase has been recommended.
Sources: en.wikipedia.org
=== Foundation: 1977 === On 2 March 1977, the General People's Congress adopted the "Declaration on the Establishment of the Authority of the People" at Gaddafi's behest. Dissolving the Libyan Arab Republic, it was replaced by the Great Socialist People's Libyan Arab Jamahiriya (Arabic: الجماهيرية العربية الليبية الشعبية الاشتراكية, al-Jamāhīrīyah al-‘Arabīyah al-Lībīyah ash-Sha‘bīyah al-Ishtirākīyah), a "state of the masses" conceptualized by Gaddafi. A new, all-green banner was adopted as the country's flag. Officially, the Jamahiriya was a direct democracy in which the people ruled themselves through the 187 Basic People's Congresses (BPCs), where all adult Libyans participated and voted on national decisions. These then sent members to the annual General People's Congress, which was broadcast live on television. In principle, the People's Congresses were Libya's highest authority, with major decisions proposed by government officials or with Gaddafi himself requiring the consent of the People's Congresses. Gaddafi became General Secretary of the GPC, although he stepped down from this position in early 1979 and appointed himself "Leader of the Revolution".
=== Excessive sweating === Methenamine, in a topical cream or gel stick formulation sold under brand names like Antihydral and Dehydral, is used in the treatment of hyperhidrosis (excessive sweating) and has been reported to be clinically effective for this indication. The skin is slightly acidic and formaldehyde can be released from methenamine in this environment.
Several studies have suggested that breast milk can pass antibodies to the infant for as long as the child continues to nurse. The antibodies may be in the mother's system as a result of being ill, or they may be acquired by drinking milk from a mother who has recently been vaccinated for a particular disease. One small study done on nursing mothers who had received the COVID-19 vaccine found that breastmilk continued to contain antibodies for as long as 80 days after receiving the vaccine.
Sources: en.wikipedia.org
Samples are transported daily to the laboratory responsible for testing. In the United States and Canada, newborn screening is mandatory, with an option for parents to opt out of the screening in writing if they desire. In many regions, NBS is mandatory, with an option for parents to opt out in writing if they choose not to have their infant screened. In most of Europe, newborn screening is done with the consent of the parents. Proponents of mandatory screening claim that the test is for the benefit of the child, and that parents should not be able to opt out on their behalf. In regions that favour informed consent for the procedure, they report no increase in costs, no decrease in the number of children screened and no cases of included diseases in children who did not undergo screening.
In one interpretation of the film's plot, a scientific process supposedly extracts hydrogen from water, then burns the hydrogen to generate power, and leaves only water as a residue, essentially a chemical perpetual motion. The movie never clarifies how the hydrogen is extracted from the water, nor how water is still left over. The character Dr. Shannon makes contradictory statements in the combination of ideas mashed together: one time he says this is accomplished with a laser with millions of degrees, another time he says frequencies of sound and sonoluminescence. In one scene, the movie shows a bubbling container reminiscent of cold fusion electrolytic cells and another reference sustained fusion. A character in the film claims that a glass of water could power Chicago for weeks, but no clear explanation is ever given as to whether this is by simply burning hydrogen released by highly efficient means or through nuclear processes. The film's title is also misleading, since "chain reaction" is related to nuclear fission, not fusion. The film is based on the premise that free energy suppression is real. The main character is told that his discovery is too disruptive: energy would suddenly be cheap, oil would no longer be necessary, oil companies would go bankrupt, and such sudden economic changes would throw society into chaos.
== History == Descriptions of a disease believed to be vitiligo date back to a passage in the Ebers Papyrus (c. 1500 BC), an ancient Egyptian medical text. Additionally, the Hebrew word "Tzaraath" from the Old Testament book of Leviticus (c. 1300 BC) described a group of skin diseases associated with white spots; a subsequent translation to Greek led to continued conflation of those with vitiligo with leprosy and spiritual uncleanliness. Medical sources in the ancient world, such as Hippocrates, often did not differentiate between vitiligo and leprosy, grouping these diseases. The historical conflation of vitiligo with leprosy contributed to social stigma surrounding the condition in many societies, despite vitiligo being neither infectious nor physically disabling. The name "vitiligo" was first used by the Roman physician Aulus Cornelius Celsus in his classic medical text De Medicina. The term vitiligo is believed to be derived from "vitium", meaning "defect" or "blemish".
=== Synthetic hydrogel dressings === Synthetic hydrogel dressings may be derived from synthetic polymers such as polyvinyl alcohol (PVA), poly(ethylene glycol) (PEG), polyurethane (PU), and poly(lactide-co-glycolide) (PLGA). Synthetic hydrogel dressings may also be formed from designer peptides. Researchers are applying 3D printing to the synthesis of hydrogel dressings.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.